| abstract |
The vaccine contains (a) a materia selected from the group containing at least one serologic form of the pC protein from Borrelia burgdorferi in a homogenous form, a pC variant and pC imitations, both stimulating antigens production, (b) a physiologically-acceptable excipient and (c) adjuvans, whereas the said materia is used in an amount useful enough to protect mammals, i.e. from 1 to 100 micrograms, preferably from 10 to 50 micrograms per a dosage. |